Peptides News and Research

RSS

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.

13 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks.

10 Feb 2013

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

UT Southwestern Medical Center scientists have synthesized a peptide that shows potential for pharmaceutical development into agents for treating infections, neurodegenerative disorders, and cancer through an ability to induce a cell-recycling process called autophagy.

10 Feb 2013

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

Scientists visualise molecular changes in Bax protein that force cells to die

Scientists at the Walter and Eliza Hall Institute have for the first time visualised the molecular changes in a critical cell death protein that force cells to die.

3 Feb 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

OncoPep, Inc. today announced that the Company has initiated a Phase 1/2a clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma, an asymptomatic precursor of multiple myeloma, which is an incurable cancer of the plasma cells.

30 Jan 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

IOF-ESCEO Pre-Clinical Symposium to be held on April 18 in Rome, Italy

Investigators with an interest in pre-clinical and translational musculoskeletal research are invited to attend the 3rd IOF-ESCEO Pre-Clinical Symposium to be held on April 18, in Rome, Italy.

29 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Left ventricular hypertrophy prevalent in lung disease patients

The prevalence of left ventricular hypertrophy is increased in normoxemic patients with chronic obstructive pulmonary disease, results from a pilot study suggest.

25 Jan 2013

Children with eczema have distinct gut microbiome

Infants with eczema have more diverse total gut microbiota than those without the skin condition, show study findings.

25 Jan 2013

Study shows promising results for cancer treatment

The plasma membrane transporter SLC5A8 can inhibit the spread of tumours by decreasing the amount of the anti-apoptotic protein surviving in tumour cells.

25 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Researchers discover unique hairpin-like structure that facilitates Abeta clumping

Alzheimer's disease is the most common cause of late-life dementia. The disorder is thought to be caused by a protein known as the amyloid-beta protein, or Abeta, which clumps together in the brain, forming plaques that are thought to destroy neurons. This destruction starts early, too, and can presage clinical signs of the disease by up to 20 years.

24 Jan 2013

Enterococcal cytolysin synthetase helps form distinctly different, 3-D protein ring structures

While working out the structure of a cell-killing protein produced by some strains of the bacterium Enterococcus faecalis, researchers stumbled on a bit of unusual biochemistry. They found that a single enzyme helps form distinctly different, three-dimensional ring structures in the protein, one of which had never been observed before.

23 Jan 2013

Researchers report novel charge zipper principle used by proteins to form functional units

Membrane proteins are the "molecular machines" in biological cell envelopes. They control diverse processes, such as the transport of molecules across the lipid membrane, signal transduction, and photosynthesis. Their shape, i.e. folding of the molecules, plays a decisive role in the formation of, e.g., pores in the cell membrane.

19 Jan 2013

Peptides News and Research

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Infusions of regulatory T cells turn off autoimmune attack on joints

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Scientists visualise molecular changes in Bax protein that force cells to die

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

Bone Medical announces initial findings from BN006 proof of concept RA study

IOF-ESCEO Pre-Clinical Symposium to be held on April 18 in Rome, Italy

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Left ventricular hypertrophy prevalent in lung disease patients

Children with eczema have distinct gut microbiome

Study shows promising results for cancer treatment

New hope for lupus patients

Researchers discover unique hairpin-like structure that facilitates Abeta clumping

Enterococcal cytolysin synthetase helps form distinctly different, 3-D protein ring structures

Researchers report novel charge zipper principle used by proteins to form functional units

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News